DGP Plc Takes Drug Testing In-house with Fingerprint Sweat-based Testing
- None.
- None.
Insights
The adoption of the Intelligent Fingerprinting Drug Screening System by DGP Plc represents a significant advancement in workplace safety and efficiency. Traditional drug testing methods, such as urine or blood tests, often require significant time away from work, which can lead to productivity losses. The introduction of a rapid, non-invasive testing method enables DGP Plc to maintain a high safety standard without the associated downtime, thus potentially reducing the number of work hours lost to testing.
Moreover, the visible commitment to a strict Drug and Alcohol Policy through regular, random testing could enhance the safety culture within the organization. By implementing such innovative technology, DGP Plc sends a clear message to its workforce regarding the importance it places on safety and sobriety on the job. This could lead to a deterrent effect, reducing the likelihood of substance abuse among employees and contractors and consequently mitigating the risk of accidents and injuries on site.
From a human resources and compliance perspective, the deployment of the Intelligent Fingerprinting system by DGP Plc is a strategic move. It streamlines the drug testing process, which not only respects the employees' time but also aligns with modern privacy and dignity considerations in the workplace. This technology allows for testing to be done discreetly and efficiently, thereby minimizing discomfort and potential stigma associated with traditional drug testing methods.
Furthermore, the system's portability and ease of use could lead to enhanced compliance with internal policies and regulatory requirements. By simplifying the testing process, DGP Plc is likely to see an increase in compliance rates, ensuring that all employees and contractors adhere to the company's Drug and Alcohol Policy. This could also serve as a competitive advantage in the industry, as it demonstrates DGP Plc's commitment to best practices in workplace health and safety.
From a financial standpoint, the investment in the Intelligent Fingerprinting Drug Screening System could result in significant cost savings for DGP Plc. The reduction in productivity loss due to the faster testing process directly translates to cost efficiency. Additionally, by managing workplace drug testing internally, DGP Plc may reduce expenses associated with external drug testing services.
The long-term financial benefits could extend beyond direct cost savings. By fostering a safer work environment and adhering to strict compliance standards, DGP Plc may also reduce potential liabilities associated with workplace incidents. This proactive approach may also lead to lower insurance premiums and could positively influence investor perception of the company's risk management strategies.
Construction logistics, security, and support specialist selects Intelligent Fingerprinting Drug Screening System to simplify and speed up workplace drug testing for its 450 employees and contractors
“By using fingerprint drug testing, I no longer have to take people off a project for half a day for screening – we can conduct the tests there and then” – Ruth Trant, SHEQ & Assurance Director, DGP Plc
NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that DGP Plc has selected the revolutionary portable Intelligent Fingerprinting Drug Screening System to enable in-house drug testing.
DGP is one of the UK’s leading construction logistics, security and support companies. Its services enable the delivery of many of the country’s largest construction projects. The company implements robust processes and risk-based SHEQ management to support the way it delivers its works, and will now use the Intelligent Fingerprinting Drug Screening System to enable faster, more convenient and more flexible workplace drug testing.
“Having already seen fingerprint sweat-based drug screening in action at another company, I knew that the Intelligent Fingerprinting would work well for DGP,” explained Ruth Trant, DGP Plc’s SHEQ & Assurance Director. “We had previously used an external drug testing service to carry out random urine-based screening, but with around 450 employees and contractors working on customer project sites at any one time, this proved highly disruptive to productivity. With fingerprint sweat-based testing we can conduct the ten-minute tests there and then, with people not having to wait. The portability of the Intelligent Fingerprinting system also means we can conduct workplace testing wherever it is needed.
“We have a duty to put people to work safely, and conducting testing sends a clear signal that coming to work under the influence of drugs or alcohol is unsafe and not acceptable at DGP Plc. We are also keen for everyone across the business to see that we take our Drug and Alcohol Policy very seriously. The fact that everyone in DGP is subject to random testing is important, while its portability means that people get to see our Intelligent Fingerprinting system in action regularly,” added Ruth.
“An increasing number of construction and logistics firms are turning to our fingerprint sweat-based system for various testing needs, from recruitment and onboarding requirements to random workplace screening or for cause testing,” added Harry Simeonidis, President and Chief Executive Officer at Intelligent Bio Solutions. “Our system’s flexibility and ease of use makes it much simpler for organizations like DGP to manage workplace drug testing internally, resulting in overall cost savings and improved productivity due to minimal disruption.”
An introductory video demonstrating fingerprint-based drug testing in action is available here.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (the “Company”) (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. This hygienic and cost-effective system is designed to screen for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company’s biosensor platform has the potential to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. The Company’s current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: www.ibs.inc
About DGP Plc
DGP Plc is a leading UK construction logistics, security, and support service contractor with an impressive track record spanning over three decades. DGP has contributed to the delivery of a range of complex and highly regulated projects across the UK, including Manchester Airport, Paddington Square, Manchester Old Town Hall, and Birmingham New Street Station.
For more information, visit: www.dgpplc.com
Forward-Looking Statements:
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Media Contact:
Cheryl Billson, Comma Communications
cheryl.billson@commacomms.com
+44 (0)7791 720460
FAQ
What drug screening system did DGP Plc select for in-house drug testing?
How many employees and contractors does DGP Plc have?
What are the benefits of the Intelligent Fingerprinting Drug Screening System?
